Free Trial

Solid Biosciences (SLDB) Competitors

Solid Biosciences logo
$5.94
+0.28 (+4.95%)
(As of 05:13 PM ET)

SLDB vs. LOGC, CSBR, PLRX, TYRA, REPL, DNTH, SANA, CRON, ANNX, and ETNB

Should you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include LogicBio Therapeutics (LOGC), Champions Oncology (CSBR), Pliant Therapeutics (PLRX), Tyra Biosciences (TYRA), Replimune Group (REPL), Dianthus Therapeutics (DNTH), Sana Biotechnology (SANA), Cronos Group (CRON), Annexon (ANNX), and 89bio (ETNB).

Solid Biosciences vs.

Solid Biosciences (NASDAQ:SLDB) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership and dividends.

In the previous week, Solid Biosciences had 1 more articles in the media than LogicBio Therapeutics. MarketBeat recorded 1 mentions for Solid Biosciences and 0 mentions for LogicBio Therapeutics. Solid Biosciences' average media sentiment score of 0.59 beat LogicBio Therapeutics' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Solid Biosciences Positive
LogicBio Therapeutics Neutral

Solid Biosciences received 170 more outperform votes than LogicBio Therapeutics when rated by MarketBeat users. Likewise, 68.15% of users gave Solid Biosciences an outperform vote while only 64.08% of users gave LogicBio Therapeutics an outperform vote.

CompanyUnderperformOutperform
Solid BiosciencesOutperform Votes
261
68.15%
Underperform Votes
122
31.85%
LogicBio TherapeuticsOutperform Votes
91
64.08%
Underperform Votes
51
35.92%

Solid Biosciences presently has a consensus price target of $15.67, indicating a potential upside of 172.94%. Given Solid Biosciences' higher probable upside, equities research analysts clearly believe Solid Biosciences is more favorable than LogicBio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.25
LogicBio Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

81.5% of Solid Biosciences shares are owned by institutional investors. Comparatively, 46.1% of LogicBio Therapeutics shares are owned by institutional investors. 13.6% of Solid Biosciences shares are owned by company insiders. Comparatively, 0.4% of LogicBio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Solid Biosciences has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500. Comparatively, LogicBio Therapeutics has a beta of 2.05, meaning that its stock price is 105% more volatile than the S&P 500.

Solid Biosciences has a net margin of 0.00% compared to LogicBio Therapeutics' net margin of -141.03%. Solid Biosciences' return on equity of -53.76% beat LogicBio Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Solid BiosciencesN/A -53.76% -43.74%
LogicBio Therapeutics -141.03%-109.05%-62.15%

Solid Biosciences has higher earnings, but lower revenue than LogicBio Therapeutics. Solid Biosciences is trading at a lower price-to-earnings ratio than LogicBio Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid Biosciences$8.09M27.67-$96.01M-$3.30-1.76
LogicBio Therapeutics$287M0.58-$317M-$9.10-0.70

Summary

Solid Biosciences beats LogicBio Therapeutics on 15 of the 18 factors compared between the two stocks.

Get Solid Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SLDB vs. The Competition

MetricSolid BiosciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$223.88M$3.14B$5.19B$8.55B
Dividend YieldN/A1.76%5.06%4.17%
P/E Ratio-1.767.62106.1014.37
Price / Sales27.67325.241,643.8695.76
Price / CashN/A147.3233.9831.46
Price / Book0.934.024.754.62
Net Income-$96.01M-$42.25M$116.42M$223.41M
7 Day Performance1.93%0.13%-0.78%-0.31%
1 Month Performance-11.85%8.39%5.58%3.98%
1 Year Performance104.23%28.33%33.83%26.39%

Solid Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SLDB
Solid Biosciences
3.0198 of 5 stars
$5.94
+4.9%
$15.67
+163.7%
+99.3%$229.25M$8.09M-1.80100Positive News
LOGC
LogicBio Therapeutics
0.449 of 5 stars
$6.49
-1.2%
N/AN/A$172.62M$287M-0.7162
CSBR
Champions Oncology
4.269 of 5 stars
$3.91
+3.2%
$6.00
+53.5%
-27.4%$51.52M$50.15M-15.04143Positive News
High Trading Volume
PLRX
Pliant Therapeutics
4.1023 of 5 stars
$14.07
-2.4%
$40.57
+188.4%
-10.1%$876.15M$1.58M-4.5590
TYRA
Tyra Biosciences
3.77 of 5 stars
$16.68
+4.4%
$31.40
+88.2%
+20.9%$843.31MN/A-9.8720Gap Up
REPL
Replimune Group
3.6904 of 5 stars
$11.76
-2.9%
$16.80
+42.9%
-15.4%$827.37MN/A-3.60210
DNTH
Dianthus Therapeutics
1.4157 of 5 stars
$27.86
-0.4%
$45.14
+62.0%
+135.7%$821.08M$2.83M-5.0380News Coverage
SANA
Sana Biotechnology
2.1364 of 5 stars
$3.50
-4.4%
$14.25
+307.1%
+6.5%$814.22MN/A-3.04328Analyst Forecast
News Coverage
Gap Down
CRON
Cronos Group
1.2971 of 5 stars
$2.09
-0.9%
$3.00
+43.5%
+18.3%$806.64M$87.24M-13.93356Upcoming Earnings
News Coverage
ANNX
Annexon
1.4105 of 5 stars
$7.32
-2.9%
$15.80
+115.8%
+173.7%$796.63MN/A-5.9560Upcoming Earnings
ETNB
89bio
1.8741 of 5 stars
$7.78
-2.6%
$31.00
+298.5%
+10.5%$786.09MN/A-3.9540Gap Down

Related Companies and Tools


This page (NASDAQ:SLDB) was last updated on 11/5/2024 by MarketBeat.com Staff
From Our Partners